14102 studies
AIMS: Glucagon-like peptide-1 receptor agonism (GLP1RA)-based therapies (GLP1RA-BTs) form the cornerstone for managing type 2 diabetes (T2D) and obesity. However, their impact on limb-specific outcomes in peripheral artery disease (PAD) remains uncle…
Obesity is a complex metabolic disorder associated with an increased risk of type 2 diabetes, cardiovascular diseases, and metabolic dysfunction-associated steatotic liver disease. While protein-based therapies like glucagon-like peptide-1 (GLP-1) re…
IMPORTANCE: The primary analysis of the SELECT randomized clinical trial suggests that semaglutide reduced the rates of cardiovascular (CV) death, myocardial infarction, and stroke in patients with established CV disease (CVD) and overweight or obesi…
BACKGROUND: Semaglutide, a glucagon-like peptide-1(GLP-1) receptor agonist, is an effective treatment for type 2 diabetes and weight loss. However, its high cost poses a significant barrier to access for those who need it more. This study investigate…
OBJECTIVE: This study compared the efficacy of a GLP-1 receptor agonist (GLP1-RA) (semaglutide, 0.5 mg/week), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and repetitive transcranial magnetic stimulation (rTMS), a new emerging treatment for ob…
AIMS: To evaluate whether Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use at immune checkpoint inhibitor (ICI) start is associated with mortality, healthcare use, and immune-related adverse events in adults with type 2 diabetes (T2D). METHODS…
Obesity is a global health issue that impacts millions of people worldwide. Semaglutide is a glucagon-like peptide-1 receptor agonist that was initially developed as a treatment for type 2 diabetes mellitus under the brand name Ozempic. Additional st…
BACKGROUND AND AIM: Semaglutide therapy improves glycaemic control, weight loss, and cardiovascular risk reduction in patients with type 2 diabetes mellitus (T2D). Sex-specific differences in the response to oral versus subcutaneous formulation remai…
CONTEXT: Recent studies suggest glucagon-like peptide receptor-1 agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP) may contribute to altered calcium metabolism. OBJECTIVE: This study examines the association between GLP-1RA/GI…
The global prevalence of diabetes mellitus (DM) and heart failure (HF) is rapidly increasing. Hyperglycemia, insulin resistance and hyperglycemia-induced oxidative stress in people with DM are the key etiological factors of HF. The factors disrupt sy…
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a newly defined clinical condition characterized by hepatic steatosis in the presence of one or more cardiometabolic risk factors (CMRFs), such as obesity, type 2 diabetes, or dyslip…
BACKGROUND: GLP- 1 RA have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1 RA inhibit progression of solid tumor malignancies via dow…
Obesity management is challenged by high rates of recurrent weight gain following initial loss. We systematically reviewed 29 randomized controlled trials comparing long-term outcomes of lifestyle interventions, semaglutide, and metabolic and bariatr…
Pharmacotherapies for metabolic dysfunction-associated steatotic liver disease (MASLD) remain limited. Although resmetirom and semaglutide have approvals for MASH, gut-liver axis options are still needed. Fatty Acid Esters of Hydroxy Fatty Acids (FAH…
Melanocortin-4 receptor (MC4R) deficiency is the most common cause of monogenic obesity; yet treatment options for children with MC4R mutations are limited. We describe significant improvement in weight in three patients with pathogenic or likely pat…
This narrative review synthesizes evidence identified through targeted searches of PubMed, Scopus, and Web of Science (2010-2025), with a focused selection of human and mechanistic studies examining GLP-1 receptor agonists (GLP-1s), food cue reactivi…
BACKGROUND: Bariatric surgery (BS) and glucagon-like peptide-1- receptor agonists (GLP-1RAs) are established treatments for obesity and cardiovascular risk, but their comparative impact on clinical outcomes remains unclear. OBJECTIVES: To compare lon…
BACKGROUND: To examine preliminary associations between enlarged perivascular spaces (ePVS) and cerebrovascular small-vessel disease, cortical atrophy, and cognitive impairment among a select cohort of Hispanic and Latino adults. The Hispanic and Lat…
INTRODUCTION: Central sleep apnea (CSA) and obstructive sleep apnea (OSA) are characterized by recurrent pauses in breathing secondary to decreased central respiratory drive and upper airway obstruction, respectively. Oropharyngeal surgery is not a t…